Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038904 · ClinicalTrials.gov registry record · Phase 2
Preventing Anaphylaxis With Acalabrutinib
A Phase 2 study of Food Allergy and Food Allergy Peanut, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05038904: Completed Phase 2 study of Food Allergy and Food Allergy Peanut, sponsored by Johns Hopkins University.
NCT05038904 is a Phase 2 study of Food Allergy and Food Allergy Peanut that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants, below the 964-participant average among 17 other Food Allergy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038904, a Phase 2 study of Food Allergy and Food Allergy Peanut, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.
Primary Outcome
The highest dose of peanut protein (in mg) tolerated during oral food challenge before and after acalabrutinib treatment was determined by assessing clinical symptoms and physcial exam findings in each organ system during the challenge. Symptoms were given a numeric score based on the American Academy of Allergy, Asthma, and Immunology/European Academy of Allergy and Clinical Immunology PRACTALL consensus system to grade symptom severity and the likelihood of their representing a true objective
Conditions Studied
Interventions
- DRUG Acalabrutinib
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
What the finished NCT05038904 record still lists
NCT05038904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 964-participant average among 17 other Food Allergy trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Food Allergy appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib is the first listed.
NCT05038904 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05038904 about?
NCT05038904 is a clinical study titled "Preventing Anaphylaxis With Acalabrutinib". Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to ...
What is the current status of trial NCT05038904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-12-16. Estimated completion is 2022-12-31.
What conditions does trial NCT05038904 study?
This clinical trial studies the following conditions: Food Allergy, Food Allergy Peanut.
What interventions are being tested in trial NCT05038904?
The interventions under investigation include: Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT05038904?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05038904 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05038904's enrollment target sits among peer trials
10 17th of 17 higher than 1 of 17 other Food Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Food Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI